Semax
Synthetic heptapeptide (ACTH 4-10 analogue). Increases the expression of BDNF and NGF in the hippocampus. Modulates dopaminergic and serotonergic receptors and activates the 'default mode network'.
- Neuroprotection (post-ischaemia/stroke)
- Increased focus and memory
- Improved mood and anxiety
- Increase in BDNFNeuroprotection (post-ischaemia/stroke)
- Increase in BDNF
- Irritation of the nasal mucosa.
- Mild excitement. Irritation of the nasal mucosa.
- Mild excitement.
Semax is a nootropic peptide developed from a fragment of adrenocorticotrophic hormone (ACTH), designed to promote neuroprotection and increase levels of brain-derived neurotrophic factor (BDNF).
READ MORE
What it is (in plain language)
- It's a 'stimulant' that doesn't use caffeine. It increases mental clarity, memory and learning speed by protecting neurons and increasing substances that help the brain grow. It is often used to recover from brain damage, such as strokes, or for periods of intensive study.
Why do you appear online so much
- It is considered one of the most effective and safe nootropics of the 'Russian school'. Biohackers use it to eliminate mental fog and increase resilience to oxidative stress in the brain without causing the 'crash' of common stimulants.
How it is framed today (pragmatic view)
- 1) Evidence: Included in the Russian list of vital and essential medicines. 2) Purpose: Cognitive optimisation and neurological recovery. 3) Risk: Very clean safety profile; may cause increased anxiety in people who are very sensitive to stimulants.
How to use this form
- Check the difference between the concentrations of 0.1% and 1% in the dosage section.
- Quick profile (curated by Subject 157)
- Class: Nootropic
- Status: Verified
- Use case: Nootropic
- Route: Nasal
- Tags: Nasal|Injectable|Focus|Brain
- Half-life: Variable
- Start: Quick (minutes)
- Duration: ~12-24 hours
- Mechanism (high level)
Synthetic heptapeptide (ACTH 4-10 analogue). Increases the expression of BDNF and NGF in the hippocampus. Modulates dopaminergic and serotonergic receptors and activates the 'default mode network'.
- Evidence (what the literature covers)
RESEARCH RANGE (Russian, Non-prescriptive):
Doses range from 200mcg to 1000mcg (Nasal/SC).
Level of Evidence: B (Extensive Russian studies, approved in Russia).
- Safety and harm-reduction (non-prescriptive)
Risks: Irritation of the nasal mucosa.
Mild excitement.
Interactions: Unknown.
- References (anchors)
- Medvedeva, E. V. (2017) - Semax immune gene regulation in ischaemia - https://doi.org/10.1007/s00438-017-1297-1 | PubMed:28639016
- Gusev, E. I. (2018) - Semax in ischemic stroke rehabilitation - https://doi.org/10.17116/jnevro20181183261-68 | PubMed:29737299
Note: Educational/research content. Does not constitute medical advice, diagnosis or prescription.
EN 
PT 
FR 
ES 
DE 
IT 
PL